These transactions were conducted through indirect ownership, specifically noted as being held by Levine's wife. Following these acquisitions, Levine's total beneficial ownership in Cardiff Oncology now stands at 67,716 shares. According to InvestingPro, the stock has demonstrated significant volatility and strong performance across multiple timeframes. For deeper insights into insider trading patterns and 15+ additional ProTips, including detailed financial health analysis, consider exploring the comprehensive Pro Research Report available on InvestingPro. According to InvestingPro, the stock has demonstrated significant volatility and strong performance across multiple timeframes. For deeper insights into insider trading patterns and 15+ additional ProTips, including detailed financial health analysis, consider exploring the comprehensive Pro Research Report available on InvestingPro.
These transactions were conducted through indirect ownership, specifically noted as being held by Levine's wife. Following these acquisitions, Levine's total beneficial ownership in Cardiff Oncology now stands at 67,716 shares.
In other recent news, Cardiff Oncology has been making significant strides in its ongoing projects. The company's ongoing randomized Phase II trial of onvansertib for first-line RAS-mutated metastatic colorectal cancer (mCRC) has shown promising initial data, with a 64% objective response rate at the 30 mg dose. This led Piper Sandler to raise the price target on Cardiff Oncology's stock from $7.00 to $10.00, maintaining an Overweight rating.
In addition to this, Cardiff Oncology has priced its public stock offering at $2.60 per share, aiming to raise approximately $40 million before fees and expenses. The funds are set to be used for clinical trial costs of onvansertib and other general corporate purposes. TD Cowen, William Blair, H.C. Wainwright & Co., and Craig-Hallum are managing and co-managing the offering.
Moreover, the company has secured a U.S. patent for the method of using onvansertib in combination with bevacizumab in the treatment of KRAS mutated metastatic colorectal cancer. The patent, issued by the United States Patent and Trademark Office, extends through 2043. These are among the recent developments for Cardiff Oncology, demonstrating its commitment to advancing novel cancer therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.